Research Article
[Retracted] The In Vitro Antimicrobial and Antibiofilm Activities of Lysozyme against Gram-Positive Bacteria
Table 1
The MICs (μg/mL) of various drugs and their combination with LYS against different species of clinical isolated GPB.
| No. | Drugs | Isolates | Use alone | Combinations | +10 μg/mL LYS | +30 μg/mL LYS |
| 1 | LZD | MRSA | 31 a | 1 | 1 | 1 | 33 | 1 | 1 | 1 | 62 | 1 | 1 | 1 | MRSE | 61 | 1 | 1 | 1 | 62 | 1 | 1 | 1 | 63 | 1 | 1 | 1 | VREF | 11 | 2 | 2 | 1 | 12 | 1 | 1 | 1 | 13 | 1 | 1 | 1 | 2 | AMK | MRSA | 31 | 1 | 1 | 1 | 33 | 2 | 1 | 4 | 62 | 2 | 4 | 4 | MRSE | 61 | <0.5 | <0.5 | <0.5 | 62 | 2 | 2 | 2 | 63 | 2 | 2 | 2 | VREF | 11 | >256 | >256 | >256 | 12 | >256 | >256 | >256 | 13 | >256 | >256 | >256 | 3 | CRO/SBT | MRSA | 31 | >256 | >256 | >256 | 33 | 32 | 32 | 16 | 62 | 8 | 8 | 8 | MRSE | 61 | >32 | >32 | >32 | 62 | 4 | 8 | 8 | 63 | 16 | 16 | 32 | VREF | 11 | >256 | >256 | >256 | 12 | >32 | >32 | >32 | 13 | >32 | >32 | >32 | 4 | CTX/SBT | MRSA | 31 | >256 | >256 | >256 | 33 | 16 | 16 | 8 | 62 | 8 | 8 | 8 | MRSE | 61 | >32 | >32 | >32 | 62 | >32 | >32 | >32 | 63 | 8 | 8 | 4 | VREF | 11 | >256 | >256 | >256 | 12 | >32 | >32 | >32 | 13 | >32 | >32 | >32 | 5 | PIP/SBT | MRSA | 31 | 256 | 256 | 128 | 33 | 16 | 16 | 8 | 62 | 8 | 8 | 4 | MRSE | 61 | 128 | 128 | 64 | 62 | 32 | 32 | 16 | 63 | 2 | 2 | 2 | VREF | 11 | >256 | >256 | >256 | 12 | >256 | >256 | >256 | 13 | >256 | >256 | >256 | 6 | DOX | MRSA | 31 | 0.5 | 0.5 | 0.5 | 33 | <0.0625 | <0.0625 | <0.0625 | 62 | 2 | 2 | 2 | MRSE | 61 | <0.0625 | <0.0625 | <0.0625 | 62 | <0.0625 | <0.0625 | <0.0625 | 63 | 1 | 1 | 1 | VREF | 11 | <0.0625 | <0.0625 | <0.0625 | 12 | 8 | 8 | 4 | 13 | <0.0625 | 0.125 | <0.0625 | 7 | LVX | MRSA | 31 | 8 | 8 | 8 | 33 | 0.25 | 0.25 | 0.25 | 62 | 0.5 | 0.5 | 0.5 | MRSE | 61 | 16 | 16 | 8 | 62 | 2 | 2 | 2 | 63 | 8 | 8 | 8 | VREF | 11 | 32 | 32 | 32 | 12 | >16 | >16 | >16 | 13 | >16 | >16 | >16 | 8 | AK71 | MRSA | 31 | 64 | 64 | 32 | 33 | 8 | 4 | 2 | 62 | 2 | 4 | <0.5 | MRSE | 61 | 32 | 16 | 8 | 62 | <0.5 | <0.5 | <0.5 | 63 | 1 | <0.5 | 1 | VREF | 11 | >256 | >256 | >256 | 12 | 128 | 128 | 128 | 13 | >256 | >256 | >256 | 9 | IPM | MRSA | 31 | 64 | 64 | 64 | 33 | 0.5 | 0.5 | 0.5 | 62 | <0.125 | <0.125 | <0.125 | MRSE | 61 | 16 | 2 | 0.5 | 62 | 0.125 | 0.25 | 0.25 | 63 | 1 | 1 | 1 | VREF | 11 | >256 | >256 | >256 | 12 | >32 | >32 | >32 | 13 | >32 | >32 | >32 | 10 | AZM | MRSA | 31 | 128 | 128 | 64 | 33 | >128 | >128 | >128 | 62 | >128 | >128 | >128 | MRSE | 61 | >128 | >128 | >128 | 62 | >128 | >128 | >128 | 63 | >128 | >128 | >128 | VREF | 11 | 1 | 1 | 1 | 12 | >256 | >256 | >256 | 13 | >128 | >128 | >128 |
|
|
A number indicated the name of clinical isolates. MICs: minimum inhibitory concentrations; GPB: Gram-positive bacteria; MRSA: methicillin-resistant Staphylococcus aureus; MRSE: methicillin-resistant Staphylococcus epidermidis; VREF: vancomycin-resistant Enterococcus faecium; LYS: lysozyme; LZD: linezolid; AMK: amikacin; CRO/SBT: ceftriaxone/sulbactam; CTX/SBT: cefotaxime/sulbactam; PIP/SBT: piperacillin/sulbactam; DOX: doxycycline; LVX: levofloxacin; AK71: amoxicillin/clavulanate potassium 7 : 1; IPM: imipenem; AZM: azithromycin; –: not tested.
|